Business Day (25 October 2021) reported that Aspen Pharmacare, agreed to sell six prescription drugs to Swiss group Acino for R1.8-bn as part of its strategy to refine its portfolio and reduce debt. The medicines are used for the treatment of gastroenterology, erectile dysfunction and cardiovascular diseases, and generated R512-m in revenue in Aspen’s 2021 year. The transaction includes the Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands, and is expected to be concluded by the end of the calendar year.

Other news